In the dominant genetic model, the GlnGln and GlnArg genotypes of XRCC1 Arg399Gln polymorphism were significantly associated with the unfavorable ORR in advanced lung cancer patients treated with platinum-based chemotherapy compared to those with the favorable 399ArgArg genotype (GlnGln+GlnArg vs. ArgArg: OR = 0.68, 95% CI, 0.54–0.86, P = 0.001, Fig. 3A, Table 4). The gene discussed is XRCC1; the disease is lung carcinoma.